Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.

ABSTRACT:

Introduction

In immunocompromised patients, SARS-CoV-2 mRNA vaccine has been used in Italy from the beginning of the vaccination campaign, but several studies have shown that the serological response of onco-hematological patients was reduced compared to healthy subjects, due to the state of immunosuppression because of both underlying disease and administered therapy.

Methods

We evaluated the association of anti-SARS-CoV-2 spike IgG titers in 215 hematological patients with clinical and demographic variables to verify if it was possible to identify predictive parameters of serological response, as well as using a control group, consisting of healthy health workers of San Carlo Hospital in Potenza. Anti-SARS-CoV2 IgG titers were evaluated after 30-45 days post second dose va

SUBMITTER: Pascale SP 

PROVIDER: S-EPMC9393554 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature